文献速递炎症性肠病

中重度克罗恩病进阶治疗疗效比较:2025 AGA证据整合

Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis.
PubMed 文献 · Gastroenterology · 2025-10-20

本系统综述与网络荟萃分析纳入28项诱导治疗和22项维持治疗随机对照试验,比较进阶疗法在中重度克罗恩病中的疗效。分析按生物制剂暴露状态分层,采用频率学方法,并使用GRADE评估证据确定性,为2025 AGA临床指南提供依据。

要点

  • 生物制剂初治患者中,英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗、risankizumab、mirikizumab和guselkumab获中高确定性证据支持。
  • 经生物制剂暴露患者中,阿达木单抗、乌司奴单抗、risankizumab、guselkumab和upadacitinib获中高确定性证据支持。
  • 活动性对照比较中,risankizumab和guselkumab优于维得利珠单抗和乌司奴单抗(中等确定性证据)。

核心结论

  • 该更新网络荟萃分析采用GRADE评估证据质量,可为中重度克罗恩病生物制剂初治和经治患者的进阶疗法定位提供依据。

研究设计与样本

  • 系统检索多个电子数据库至2024年8月14日,纳入中重度克罗恩病成人随机对照试验,比较进阶疗法与安慰剂或另一种活性对照。
  • 共识别28项诱导治疗试验和22项维持治疗试验,采用频率学方法进行网络荟萃分析,并按生物制剂暴露状态分层。
  • 使用GRADE方法评估证据确定性。

主要发现

  • 生物制剂初治患者中,中高确定性证据支持英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗、risankizumab、mirikizumab和guselkumab优于无治疗诱导缓解;低确定性证据支持certolizumab pegol和upadacitinib。
  • 生物制剂初治患者活动性对照比较中,中高确定性证据支持阿达木单抗和乌司奴单抗优于certolizumab pegol和upadacitinib。
  • 经生物制剂暴露患者中,中高确定性证据支持阿达木单抗、乌司奴单抗、risankizumab、guselkumab和upadacitinib优于无治疗诱导缓解;低确定性证据支持维得利珠单抗和mirikizumab。
  • 经生物制剂暴露患者活动性对照比较中,中等确定性证据支持risankizumab和guselkumab优于维得利珠单抗和乌司奴单抗。

关键数值与推荐

  • 主要结局为诱导和维持临床缓解,分析按生物制剂暴露状态分层。
  • 生物制剂初治患者中,中高确定性证据支持英夫利西单抗、阿达木单抗、维得利珠单抗、乌司奴单抗、risankizumab、mirikizumab和guselkumab优于无治疗。
  • 经生物制剂暴露患者中,中高确定性证据支持阿达木单抗、乌司奴单抗、risankizumab、guselkumab和upadacitinib优于无治疗。
  • 活动性对照比较中,中高确定性证据支持阿达木单抗和乌司奴单抗优于certolizumab pegol和upadacitinib(初治患者);中等确定性证据支持risankizumab和guselkumab优于维得利珠单抗和乌司奴单抗(经治患者)。

临床怎么用

  • 对于生物制剂初治的中重度克罗恩病患者,可优先考虑获中高确定性证据支持的进阶疗法。
  • 对于经生物制剂暴露的中重度克罗恩病患者,可优先考虑获中高确定性证据支持的进阶疗法。
  • 在活动性对照选择中,可参考网络荟萃分析结果进行进阶疗法定位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We performed an updated systematic review and network meta-analysis to inform the 2025 American Gastroenterological Association Clinical Guidelines on the management of moderate-to-severe Crohn's disease (CD). METHODS: We searched multiple electronic databases from inception through August 14, 2024, to identify randomized controlled trials in adults with moderate-to-severe CD, comparing advanced therapies (eg, tumor necrosis factor antagonists, vedolizumab, interleukin 12/23, or interleukin 23p19 antagonists, and/or Janus kinase inhibitors) with placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission; analyses were stratified by biologic therapy exposure status. We performed a network meta-analysis using a frequentist approach and applied the Grading of Recommendations, Assessment, Development and Evaluation to appraise certainty of evidence. RESULTS: We identified 28 trials of induction therapy and 22 trials of maintenance therapy of advanced therapies in patients with moderate-to-severe CD. In biologic-naïve patients, moderate-to-high certainty evidence supported the use of infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, and guselkumab, and low certainty evidence supported the use of certolizumab pegol and upadacitinib over no treatment for inducing remission. Among active comparators, moderate-to-high certainty evidence supported the use of adalimumab and ustekinumab compared with certolizumab pegol and upadacitinib. Among patients with prior exposure to biologics, moderate-to-high certainty evidence supported the use of adalimumab, ustekinumab, risankizumab, guselkumab, and upadacitinib, and low certainty evidence supported the use of vedolizumab and mirikizumab, over no treatment, for inducing remission. Among active comparators, moderate certainty evidence supported the use of risankizumab and guselkumab compared with vedolizumab and ustekinumab. CONCLUSIONS: Using Grading of Recommendations, Assessment, Development and Evaluation to appraise quality of evidence, this updated network meta-analysis can inform positioning of advanced therapies for the treatment of biologic-naïve and biologic-exposed patients with moderate-to-severe CD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Singh S, Murad MH, Yuan Y, et al. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis. Gastroenterology. 2025. PMID: 41114682. doi:10.1053/j.gastro.2025.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。